Edition:
United States

Profile: Calithera Biosciences Inc (CALA.O)

CALA.O on Nasdaq

3.71USD
26 Jun 2019
Change (% chg)

$-0.04 (-0.93%)
Prev Close
$3.74
Open
$3.75
Day's High
$3.89
Day's Low
$3.43
Volume
795,180
Avg. Vol
268,381
52-wk High
$6.90
52-wk Low
$3.43

Calithera Biosciences, Inc., incorporated on March 9, 2010, is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Company is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase.

CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-839 binds to a site on glutaminase that is distinct from the site that binds glutamine, thereby reducing the potential for undesirable side effects due to inhibition of other enzymes and receptors that bind glutamine. In preclinical studies, CB-839 has been shown to halt the growth of or kill cancer cells across a range of tumor types. In addition, CB-839 has shown synergy with immunomodulatory agents and several kinase inhibitors that target growth factor pathways. The Company is enrolling patients in a series of combination Phase Ib cohorts in specific solid tumor types. Arginine is an amino acid that is fundamental to the function of cytotoxic T cells. In response to tumor-secreted factors, myeloid-derived suppressor cells (MDSCs) accumulate in the tumor and secrete the enzyme arginase, resulting in depletion of arginine from the tumor microenvironment. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

The Company competes with Advanced Cancer Therapeutics, LLC, Aeglea Biotherapeutics, Inc., Agios Pharmaceuticals, Inc., Bayer Pharma AG, Celgene Corporation, Cornerstone Pharmaceuticals, Inc., Eli Lilly and Company, Forma Therapeutics Holdings, LLC, GlaxoSmithKline plc, Novartis International AG, Quantum Pharmaceuticals, 3-V Biosciences, Inc., Rhizen Pharmaceuticals SA, Sprint Biosciences, Takeda Pharmaceutical Co. Ltd., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, CureTech Ltd., Eli Lilly and Company, Merck KGaA,, Fortress Biotech, Inc., Incyte Corporation, iTeos Therapeutics SA, Merck & Co., NewLink Genetics Corporation, Novartis International AG, Ono Pharmaceuticals, Co., Ltd, Pfizer Inc., Roche Holdings AG, Sanofi-aventis Groupe, Takeda Company Limited and TG Therapeutics, Inc.

Company Address

Calithera Biosciences Inc

343 Oyster Point Blvd # 200
SOUTH SAN FRANCISCO   CA   94080-1913
P: +1650.8701000
F: +1302.6555049

Company Web Links